Vical Reports Fourth Quarter 2017 Financial and Operational Results
March 15, 2018 06:30 ET
|
Vical Incorporated
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended December 31, 2017. Net loss for the fourth quarter of 2017...
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
March 08, 2018 21:07 ET
|
Vical Incorporated
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2017, before the...
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
March 08, 2018 16:05 ET
|
Vical Incorporated
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2018, before the...
Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
February 20, 2018 06:00 ET
|
Vical Incorporated
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the initiation of a Phase 2 trial of the Company’s VL-2397 novel antifungal compound. The multicenter,...
Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
February 01, 2018 06:30 ET
|
Vical Incorporated
SAN DIEGO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium (MSGERC) today announced the establishment of a...
Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
January 30, 2018 16:15 ET
|
Vical Incorporated
SAN DIEGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced a restructuring to conserve capital and to focus its efforts on VL-2397, its antifungal drug product...
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
January 22, 2018 03:00 ET
|
Vical Incorporated
TOKYO and SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ:VICL) announced today...
Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
November 08, 2017 06:30 ET
|
Vical Incorporated
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock...
Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
October 24, 2017 06:30 ET
|
Vical Incorporated
SAN DIEGO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that it is pursuing early stage development of a novel treatment for chronic hepatitis B virus (CHB)...
Vical Reports Third Quarter 2017 Financial and Operational Results
October 23, 2017 06:30 ET
|
Vical Incorporated
SAN DIEGO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2017. Net loss for the third quarter of 2017...